Pharmaceuticals · Nasdaq: SNY
Sanofi earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 28 Jan 2027
Latest: Q3 2026
Sanofi expanded its Regeneron alliance with four long-acting immunology antibodies to prepare for Dupixent's loss of exclusivity, while cutting pipeline programs and divesting mature medicines.
Demand for Dupixent and the newer launches drove the quarter. Dupixent is now treating more than 1.5 million patients and is still led by demand, with only about 20% of atopic dermatitis patients on advanced therapies. Launches such as ALTUVIIIO, Ayvakit and Rezurock grew strongly, and three new rare-disease medicines reached patients in China. Vaccines slipped because flu deliveries shifted into the fourth quarter and the CDC placed a smaller Beyfortus order. Sanofi also cleared out part of its legacy portfolio through a Cheplapharm partnership.
Quarters
KPI history
20-F filings
- 17 Feb 202620-F for the period ended 31 Dec 2025SEC ↗
- 13 Feb 202520-F for the period ended 31 Dec 2024SEC ↗
- 23 Feb 202420-F for the period ended 31 Dec 2023SEC ↗
- 24 Feb 202320-F for the period ended 31 Dec 2022SEC ↗
- 23 Feb 202220-F for the period ended 31 Dec 2021SEC ↗
- 4 Mar 202120-F for the period ended 31 Dec 2020SEC ↗
- 5 Mar 202020-F for the period ended 31 Dec 2019SEC ↗
- 8 Mar 201920-F for the period ended 31 Dec 2018SEC ↗